News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus
Photo from Erman Akkus/X
May 24, 2024, 14:27

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“First-line mFOLFIRINOX for GI high-grade neuroendocrine neoplasms?

  • ORR: 77% (complete response: 3%; partial response: 74%)
  • mPFS: 12 months
  • mOS: 20.6 months

Retrospective, n=35.

Prospective clinical trials are needed, may be considered in patients with high tumor burden and who can tolerate.”

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman AkkusFirst-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

 

Read further.
Source: Erman Akkus/X

Ankara University cancer Erman Akkus First-line mFOLFIRINOX high grade neuroendocrine neoplasms high tumor burden mFOLFIRINOX OncoDaily Oncology Prospective clinical trials
Special Coverage
Blog
Dec 21, 2024, 18:22
Arif Kamal: Visits to our Hope Lodge communities never cease to inspire
Blog
Dec 21, 2024, 18:14
Benedikt Westphalen: Announcing the ESMO Precision Oncology Working Group
Insight
Dec 21, 2024, 17:34
COTA has announced a partnership with precision oncology pioneer Guardant Health
Blog
Dec 21, 2024, 14:10
Arif Kamal: Ensuring all people have access to the cancer navigation services that will help them live more and better days
Blog
Dec 21, 2024, 14:06
The Accelerate 2025 Annual Conference Agenda Is Here!
Blog
Dec 21, 2024, 14:03
Pioneer the future of discovery and innovation with a fully funded Bicentenary PhD Studentship at The University of Manchester
Blog
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention - DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
Blog
Dec 21, 2024, 13:51
The ESMO President Letter emphasises the importance of collective action to shape the future of oncology
Blog
Dec 21, 2024, 13:48
Overcoming recurrence: How research is bringing new hope for breast cancer patients - The Institute of Cancer Research
Blog
Dec 21, 2024, 13:46
IARC - Cancer Incidence in Five Continents, Vol XII
Blog
Dec 21, 2024, 13:43
National University Cancer Institute, Singapore clinicians had the exciting opportunity to present their work at the ESMO Asia 2024
Blog
Dec 21, 2024, 13:40
UICC - Welcoming the newest member, The World Hepatitis Alliance